Showing results (61-70 of 681) with videos related to
Sort By:
Pageof 69
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosisLucia Masarova, Srdan VerstovsekExpert Opinion on Emerging Drugs|May 4, 2019
Emerging drugs for essential thrombocythemiaLucia Masarova, Srdan VerstovsekJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non NocereLucia Masarova, Srdan VerstovsekCurrent Hematologic Malignancy Reports|March 5, 2024
Management of Patients with Early Myelofibrosis: A Discussion of Best PracticesPrithviraj BoseExpert Opinion on Investigational Drugs|April 28, 2011
New JAK2 inhibitors for myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan VerstovsekFuture Oncology (London, England)|September 15, 2015
A comprehensive review of pacritinib in myelofibrosisSrdan Verstovsek, Rami S KomrokjiExpert Review of Hematology|October 30, 2014
Novel and emerging therapies for the treatment of polycythemia veraSrdan Verstovsek, Rami S KomrokjiCancer|July 19, 2011
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan VerstovsekExpert Opinion on Investigational Drugs|February 26, 2013
Investigational Janus kinase inhibitorsConstantine S Tam, Srdan VerstovsekPageof 69